CD11b
Colorectal cancer
DIP2A
FSTL1
LAG3
immune dysfunction
metastasis
tumor evasion
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
07
2021
accepted:
01
09
2021
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
8
12
2021
Statut:
epublish
Résumé
Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, and tumor metastasis is the leading cause of death. Targeting immune inhibitory checkpoint inhibitory pathways has attracted great attention, since the therapeutic efficacy induced by the specific blocking antibodies has been demonstrated even in metastatic CRC patients. However, the clinical outcome is low in many cases, and thus more effective treatments are needed in the clinical settings. A SPARC family member follistatin-like 1 (FSTL1) is known as a key driver of tumor metastasis in various types of cancer. However, the immunological roles of the FSTL1 in the CRC pathogenesis remain to be elucidated. In this study, we investigated the molecular mechanisms underlying the refractory FSTL1
Types de publication
Journal Article
Langues
eng
Pagination
5428-5439Informations de copyright
AJCR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Clin Cancer Res. 2014 Oct 15;20(20):5322-30
pubmed: 25139339
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
Cell Rep. 2018 Aug 14;24(7):1790-1801
pubmed: 30110636
Blood Adv. 2020 Apr 14;4(7):1367-1377
pubmed: 32267932
Cancer Res. 2017 Nov 1;77(21):5886-5899
pubmed: 28883005
Nat Rev Immunol. 2009 Jul;9(7):465-79
pubmed: 19521399
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
Cancer Cell. 2009 Mar 3;15(3):195-206
pubmed: 19249678
Cancer Biomark. 2017 Jul 19;20(1):75-85
pubmed: 28655132
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Eur J Immunol. 2005 Jul;35(7):2081-8
pubmed: 15971272
Oncogene. 2019 Apr;38(15):2706-2721
pubmed: 30542120
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Cells. 2020 Feb 27;9(3):
pubmed: 32120774
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Immunol. 2009 Feb 15;182(4):1885-91
pubmed: 19201841
Cancer Res. 2013 Oct 15;73(20):6185-93
pubmed: 23966294
Br J Cancer. 2017 Jun 27;117(1):1-7
pubmed: 28524159
Ann Transl Med. 2019 Nov;7(21):606
pubmed: 32047767
Oncol Rep. 2018 Jan;39(1):13-20
pubmed: 29115636
Future Oncol. 2020 Aug;16(23):1715-1736
pubmed: 32501724
ESMO Open. 2019 Mar 12;4(2):e000482
pubmed: 31231559
Cancers (Basel). 2019 Aug 20;11(8):
pubmed: 31434339
Cancer Immunol Res. 2015 Jun;3(6):668-77
pubmed: 25672396
Methods Enzymol. 2006;417:256-73
pubmed: 17132510
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Cell Death Dis. 2018 May 29;9(6):654
pubmed: 29844309
Cancers (Basel). 2021 Feb 01;13(3):
pubmed: 33535613
Carcinogenesis. 2009 Jan;30(1):114-21
pubmed: 18796737